India's top drugmaker by revenue Sun Pharma on Monday launched its anti-baldness drug Leqselvi in the U.S., following the ...

The drug is indicated for the treatment of alopecia areata - a condition in which the immune system attacks hair follicles, ...

LEQSELVI has been approved by the US FDA, following strong results from clinical trials and is now available to adults ...

MUMBAI: India’s equity benchmarks snapped a four-session losing streak on Tuesday, as lower-than-expected domestic inflation ...

After resolving a patent dispute with Incyte, Sun Pharma has officially launched its JAK inhibitor Leqselvi in the U.S. | Sun ...

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia ...

Sun Pharma shares surged after a settlement with Incyte over Leqselvi, a drug for severe hair loss. The agreement includes a ...

Sun recieved approval from the US Food and Drug Administration for Leqselvi in July 2024. Soon after the regulator’s approval ...

Shares of Sun Pharma rose 2 percent to Rs 1,711 in morning trade on July 15, extending their gains for a third straight ...

Shares of Sun Pharmaceutical Industries climbed nearly 3 per cent on Tuesday after the firm said it has inked a settlement pact with US-based Incyte Corporation regarding Leqselvi, a drug used for ...

Sun Pharmaceutical Industries has reached a settlement with Incyte Corporation regarding the Leqselvi drug, used for severe ...

Leqselvi (deuruxolitinib) 8 mg tablets are approved for adults with severe alopecia areata, a disease that causes the immune system to attack hair follicles, leading to partial or complete hair loss ...